Chenodiol
Orphan DrugFDA Approved (2025)
Contents
Description
Oral chenodeoxycholic acid for cerebrotendinous xanthomatosis, the first FDA-approved treatment for this rare bile-acid synthesis disorder. Approved 2025.
Indications & Therapeutic Use
Cerebrotendinous xanthomatosis (CTX)
Linked Diseases:
Global Availability (1 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| Standard Marketing Authorization | — | — | Approved |
Buy / Source Chenodiol — GNH India
10 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Chenodeoxycholic
250mgcapsuleGermany
Chenodeoxycholic acid 250mg
250mgcapsuleSpain
Chenodeoxycholic Acid Leadiant
EU
KENDEO 250 MG
250mgcapsuleTurkey
Xebyl
EU
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Chenodiol
| Generic Name | chenodiol |
| Brands | 1 brand available |
| Active Ingredient | chenodeoxycholic acid |
| Drug Class | Cerebrotendinous xanthomatosis (CTX) |
| Manufacturer | Mirum Pharmaceuticals |
| Medical Code | A05AA01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved (2025) |
| Countries | 1 countries |
Authority Signals
Last Verified7/24/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes